Ronald Cooper
Chief Executive Officer bei ALBIREO PHARMA, INC.
Vermögen: 38 665 $ am 31.03.2024
Profil
Ronald H.
W.
Cooper is currently the President, Chief Executive Officer & Director at Albireo AB.
He is also the Chief Executive Officer at Albireo Pharma, Inc., starting in 2015.
Additionally, he serves as a Director at Albireo Ltd.
since 2015 and as an Independent Director at Generation Bio Co. since 2021.
Previously, Mr. Cooper worked as an Independent Director at Genocea Biosciences, Inc. from 2016 to 2021.
Prior to that, he held the position of President-Europe at Bristol Myers Squibb Co. from 2008 to 2015.
Mr. Cooper completed his undergraduate degree at St. Francis Xavier University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GENERATION BIO CO.
0,01% | 08.06.2023 | 9 500 ( 0,01% ) | 38 665 $ | 31.03.2024 |
Aktive Positionen von Ronald Cooper
| Unternehmen | Position | Beginn |
|---|---|---|
| ALBIREO PHARMA, INC. | Chief Executive Officer | 01.06.2015 |
| GENERATION BIO CO. | Director/Board Member | 01.03.2021 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Director/Board Member | 01.09.2015 |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Ronald Cooper
| Unternehmen | Position | Ende |
|---|---|---|
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | 12.04.2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.11.2015 |
Ausbildung von Ronald Cooper
| St. Francis Xavier University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
| Generation Bio Co. |
